Response and survival benefit with chemoimmunotherapy in Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

E-ISSN： 1099-1069|36|1|93-97

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 93-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alemtuzumab: Adenovirus and enterovirus infection and Epstein-Barr virus-positive diffuse large B-cell lymphoma in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1197, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Tocilizumab for severe cytokine‐release syndrome after haploidentical donor transplantation in a patient with refractory Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 324-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Azathioprine: Diffuse large B-cell lymphoma associated with Epstein-Barr virus in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1343, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Antithymocyte globulin/ciclosporin: Epstein-Barr virus-associated diffuse large B cell lymphoma: case report

Reactions Weekly, Vol. 1, Iss. 1400, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Epstein‐Barr virus lytic cycle involvement in diffuse large B cell lymphoma

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 98-103

John Wiley & Sons Inc

Access to resources Recommend Favorite